How much did Medicare Part D spend on Ozempic in 2024?

How much did Medicare Part D spend on Ozempic in 2024?

Medicare Part D spent $12.97 billion ($12,970,296,347) on Ozempic in 2024, according to CMS’s Medicare Part D Spending by Drug data, across 10,417,182 claims and 1,952,637 beneficiaries. That is an average of $6,642 per beneficiary. The figure is gross drug cost before manufacturer rebates, which CMS does not publish.

That was 46 percent of the $27.90 billion Part D spent on all GLP-1 brands in 2024.

Ozempic in Medicare Part D, by year

YearSpendingClaimsBeneficiariesAverage per beneficiary
2020$1,455,812,2671,204,138269,663$5,399
2021$2,621,694,3482,016,177458,643$5,716
2022$4,628,160,6433,410,839780,253$5,932
2023$9,194,048,4356,927,9721,464,468$6,278
2024$12,970,296,34710,417,1821,952,637$6,642

Every semaglutide brand in Part D, 2024

Ozempic$12,970,296,34710,417,1821,952,637$1,245$6,642
Rybelsus$1,890,082,0261,251,733309,993$1,510$6,097
Wegovy$301,283,291211,57552,961$1,424$5,689

CMS describes the Part D figures this way, in its catalog entry for the dataset:

“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”

“The Part D spending metrics do not reflect any manufacturers’ rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”

Ozempic in Medicaid, 2024

Medicaid pharmacy reimbursements for Ozempic were at least $3.37 billion in 2024 across at least 3,278,476 prescriptions, from CMS’s national State Drug Utilization Data rows. State by state: Medicaid spending on GLP-1 drugs by state.

Common questions

Is the Ozempic figure what Medicare actually paid after rebates?

No. CMS says its Part D spending metrics are based on gross drug cost, including Medicare, plan and beneficiary payments, and do not reflect manufacturer rebates or other price concessions, which CMS does not publish.

How much did Medicare Part D spend on Wegovy in 2024?

Medicare Part D spent $301.3 million ($301,283,291) on Wegovy in 2024, according to CMS’s Medicare Part D Spending by Drug data, across 211,575 claims and 52,961 beneficiaries. That is an average of $5,689 per beneficiary. The figure is gross drug cost before manufacturer rebates, which CMS does not publish.

How much did Medicare Part D spend on Mounjaro in 2024?

Medicare Part D spent $6.34 billion ($6,336,942,641) on Mounjaro in 2024, according to CMS’s Medicare Part D Spending by Drug data, across 5,105,397 claims and 894,581 beneficiaries. That is an average of $7,084 per beneficiary. The figure is gross drug cost before manufacturer rebates, which CMS does not publish.

All GLP-1 brands and years: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.